Writing in KPLU’s “Humanosphere” blog, Tom Paulson responds to last week’s announcement of results from an ongoing clinical trial of an experimental malaria vaccine, saying, “Despite the hype and fanfare, many experts at the Seattle meeting said this experimental vaccine (known as RTS,S) actually so far represents only incremental progress — a scientific achievement which may still turn out to have little practical utility in the real world.” Paulson says “the findings largely repeat earlier ‘interim’ results”; the cost of the vaccine, which has not yet been confirmed; and difficulty developing a malaria vaccine that offers an acceptable level of protection are reasons why the vaccine may not be successful (10/25).